Form 4: Co-Diagnostics Director Ted Murphy Acquires Shares Through Vesting of Restricted Stock Units
SEC Form 4
Director Ted Murphy of Co-Diagnostics, Inc. acquired 48,333 shares of common stock through the vesting of restricted stock units on November 23, 2024.
Summary
- Ted Murphy, a director at Co-Diagnostics, Inc., acquired 48,333 shares of common stock on November 23, 2024.
- This acquisition was a result of the vesting of restricted stock units (RSUs).
- The RSUs were part of grants awarded to Mr. Murphy under the company's 2015 Long Term Incentive Plan.
- The vested RSUs are part of four separate grants awarded on July 7, 2022, January 17, 2023, June 12, 2023 and April 26, 2024.
- The vesting schedule for each grant is six equal installments every six months.
- Following the transaction, Mr. Murphy directly owns 175,833 shares of common stock and 151,667 restricted stock units.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction related to executive compensation, which is generally viewed neutrally to positively. The vesting of shares is a positive sign of the director meeting the conditions of the incentive plan.
Positives
- The vesting of restricted stock units indicates that the director is meeting the conditions of the incentive plan.
- The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.
Industry Context
This is a routine transaction related to executive compensation and is common in publicly traded companies. It reflects the company's long-term incentive plan for its directors.
Comparison to Industry Standards
- The use of restricted stock units as part of executive compensation is a common practice among publicly traded companies, including those in the biotechnology and diagnostics sectors.
- Companies like Abbott Laboratories, Danaher Corporation, and Thermo Fisher Scientific also utilize similar equity-based compensation plans for their executives and directors.
- The vesting schedules, typically over several years, are designed to align the interests of the executives with the long-term performance of the company.
Stakeholder Impact
- The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.
- The vesting of shares does not have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2022-07-07 | Date of first RSU grant of 70,000 units, vesting in six equal installments every six months commencing on November 23, 2022. |
| 2023-01-17 | Date of second RSU grant of 40,000 units, vesting in six equal installments every six months commencing on May 23, 2023. |
| 2023-06-12 | Date of third RSU grant of 70,000 units, vesting in six equal installments every six months commencing on November 23, 2023. |
| 2024-04-26 | Date of fourth RSU grant of 110,000 units, vesting in six equal installments every six months commencing on November 23, 2024. |
| 2024-11-23 | Date of the reported transaction where 48,333 shares were acquired through vesting of RSUs. |
| 2024-11-25 | Date of the signature on the SEC Form 4. |
Keywords
Co-Diagnostics, Director, Ted Murphy, Restricted Stock Units, Stock Acquisition, Incentive Plan, Vesting, CODX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.